Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Desktop Genetics Ltd.. (10/4/17). "Press Release: Desktop Genetics Opens £1.5 Million Investment to Support Growth". London.

Organisations Organisation Desktop Genetics Ltd. (DGT)
  Organisation 2 SyndicateRoom (GB)
Products Product bioinformatics (biological software and databases)
  Product 2 crowdfunding
Index term Index term Desktop Genetics–SEVERAL: investment, 201710– financing round £1.5m start announced via online investment platform SyndicateRoom
Persons Person Milner, Jonathan (Abcam 201409 Deputy Chairman + largest shareholder before CEO + Co-founder)
  Person 2 Doyle, Riley (Desktop Genetics Ltd 201308 CEO)

Desktop Genetics Ltd (DTG), a software company revolutionising the way biologists use CRISPR genome editing technology, and online investment platform SyndicateRoom today announce the opening of a £1.5 million investment round. DTG plans to use the funds to commercialise products and support its expansion into the US.

DTG uses artificial intelligence (AI) to enable scientists and researchers to capitalise on genome engineering technology. Since its launch in 2012, the company has developed an industry-leading software platform to design and manufacture CRISPR1 genome editing reagents, and has developed and refined products which are now ready for launch.

The genome engineering market is estimated to be worth approximately $2.84 billion globally, and set to grow to more than $6 billion by 2021, by which time it is estimated that between 60,000 and 100,000 labs will be using CRISPR technology. Despite this, over half of all new medicines in development today are likely to never reach patients, often because they are based on flawed science. DTG believes that the advances in both AI and CRISPR can together help solve this problem by enabling higher confidence in preclinical development programmes.

“Desktop Genetics has proven its ability to deliver value to customers, and has established a strong pipeline, with key research milestones hit since the 2015 investment round. This funding round provides a great opportunity as we gear up for further growth, resourcing future initiatives, hiring new team members and launching fresh products,” commented Riley Doyle, CEO, DTG. “We’re excited to open up this opportunity and welcome investors to join us on our path to success. With its extensive experience in the biotech space, SyndicateRoom is the ideal partner to connect us to those investors.”

Jonathan Milner, lead investor in Desktop Genetics, and Co-Founder and Deputy Chairman of Abcam plc, said: “Desktop Genetics’ management team has established a lucrative niche in the industry, which has seen the company make a real impact for researchers working with CRISPR technology. I am pleased to be leading this next round of investment and look forward to helping guide the next stage of the company’s growth.”

Desktop Genetics’ use of AI in customising CRISPR Libraries is enabling more efficient drug discovery, genomics and cell therapy – which is a massive step towards the reality of genomic medicine,” commented Tom Britton, CTO and Co-founder, SyndicateRoom. “We’re pleased to welcome the Desktop Genetics team to the SyndicateRoom platform as yet another young British business doing great things in a bid to make the world a better place.”

Notes to editors

1 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is a system which allows for permanent manipulation of genes in living cells and organisms, and is being explored as a method to correct the human genome for treatment of genetic diseases. CRISPR technology is credited for driving the growth in the genome engineering market.


For further information please contact:

Katie de Cozar Rushforth
+ 44 (0) 7557 307 769

Zyme Communications
Lorna Cuddon
+44 (0)7811 996 942

Desktop Genetics
Victor B Dillard
COO and Founder

Notes to Editors

About Desktop Genetics

Desktop Genetics is a recognised leader in CRISPR technology, staffed by a team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. The Company provides genome editing products and services to pharmaceutical, academic and biotechnology customers globally. Desktop Genetics' tools and technologies have been used by over 1800 organisations all over the world. Their projects have directly contributed to several key programmes to bring genome editing into the clinic.The Company has received awards from MIT Technology Review, Forbes, Fast Company and SxSW.

About SyndicateRoom

SyndicateRoom connects ambitious investors with the country’s most trailblazing companies. Started in 2013, SyndicateRoom has rapidly grown to have more than 100 high-growth businesses in its portfolio. By relentlessly focusing on the interests of private investors, SyndicateRoom has developed a trusted reputation and has been recognised as Best Investment Platform at the Growth Investor Awards two years running. For more information please visit:

Record changed: 2021-04-21


Picture [iito] Made Without Love 650x80px

More documents for Desktop Genetics Ltd. (DGT)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top